# US 2001/0043924 A1 · Antibacterial therapy with bacteriophage physico-chemically altered to delay inactivation by the host defense system

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0043924 A1
- Document ID: US20010043924A1
- Status: Published application
- Kind: A1
- Application number: 09/865,717
- Filed: 2001-05-29
- Published: 2001-11-22
- Earliest claimed: 1994-04-05
- Assignees: Exponential Biotherapies, Inc.
- Inventors: Richard M. Carlton; Carl R. Merril; Sankar L. Adhya
- Web page: https://patentgrep.com/patent/US20010043924A1

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2795/10332: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention is directed to bacteriophage therapy, using methods which enable the bacteriophage to delay inactivation by any and all parts of the host defense system (HDS) against foreign objects. The HDS normally reduces the number of bacteriophage in an animal, which decreases the efficiency of the bacteriophage in killing the host bacteria present during an infection. Disclosed is a method of producing bacteriophage modified for anti-HDS purposes by physico-chemical alteration of the bacteriophage surface proteins, so that the altered bacteriophage remain active in the body for longer periods of time than the unmodified bacteriophage.

## Claims

### Claim 1

A method for treating an infectious disease caused by a bacteria, in an animal, comprising:
administering to an animal in need of such treatment, a lytic or non-lytic physico-chemically altered bacteriophage that is specific for said bacteria, in a dosage effective to substantially eliminate the bacteria, wherein said physico-chemically altered bacteriophage has a delayed inactivation by an animal's host defense system (HDS).

### Claim 2 (depends on 1)

The method according to claim 1, wherein said bacteria is a drug resistant bacteria.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said animal is not a mammal.

### Claim 4 (depends on 1)

The method according to claim 1, wherein said animal is a mammal.

### Claim 5 (depends on 4)

The method according to claim 4, wherein said mammal is a human.

### Claim 6 (depends on 1)

The method according to claim 1, wherein said physico-chemically altered bacteriophage is PEGylated.

### Claim 7 (depends on 1)

The method according to claim 1, wherein said physico-chemically altered bacteriophage has at least a 15% longer half-life than a corresponding wild-type phage.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the bacteria is selected from the group consisting of Mycobacteria, Staphylococci, Vibrio, Enterobacter, Enterococci, Escherichia, Haemophilus, Neisseria, Pseudomonas, Shigella, Serratia, Salmonella and Streptococci, and the bacteriophage can effectively lyse the bacteria.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the bacteria is selected from the group consisting of M. tuberculosis, M. avium-intracellulare and M. bovis.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the bacteriophage is administered by way of an aerosol to an animal's lungs.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the bacteriophage is administered at a dosage of about 106 to about 1013 pfu/kg/day.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the bacteriophage is administered at a dosage of about 1012 pfu/kg/day.

### Claim 13 (depends on 1)

The method according to claim 1, wherein said bacteriophage is genetically modified to evade the HDS.

### Claim 14

A physico-chemically altered bacteriophage which is able to delay inactivation by an animal's host defense system.

### Claim 15 (depends on 14)

The bacteriophage according to claim 14, wherein said bacteriophage has at least a 15% longer half-life than a corresponding wild-type phage.

### Claim 16 (depends on 14)

The bacteriophage according to claim 14, wherein said phage is specific for bacterial families selected from the group consisting of Escherichia, Klebsiella, Shigella, Salmonella, Serratia, Yersinia, Enterobacter, Enterococci, Haemophilus, Mycobacteria, Neisseria, Pseudomonas, Staphylococci, Streptococci and Vibrio.

### Claim 17 (depends on 14)

The bacteriophage according to claim 14, wherein said bacteriophage is PEGylated.

### Claim 18

A method of obtaining a physico-chemically altered bacteriophage that is able to delay inactivation by an animal's host defense system against foreign bodies, comprising the steps of:
(a) protecting tail proteins on a bacteriophage, and
(b) then binding a polymer to any unprotected proteins on said bacteriophage.

### Claim 19 (depends on 18)

The method according to claim 18, wherein said polymer is polyethylene glycol (PEG).

### Claim 20

A method for treating an infectious disease caused by a bacteria, comprising administering to an animal in need of such treatment an antibiotic and/or a chemotherapeutic agent, in combination with a physico-chemically altered bacteriophage specific for said bacteria, in a dosage effective to substantially eliminate the bacteria, wherein said physico-chemically altered bacteriophage is able to delay inactivation by the animal's host defense system.

### Claim 21 (depends on 20)

The method according to claim 20, wherein said physico-chemically altered bacteriophage is PEGylated.

### Claim 22

A pharmaceutical composition comprising a physico-chemically altered bacteriophage which is able to delay inactivation by an animal's host defense system, in combination with a pharmaceutically acceptable carrier.

### Claim 23 (depends on 22)

The pharmaceutical composition according to claim 22, wherein said physico-chemically altered bacteriophage is PEGylated.

### Claim 24 (depends on 22)

The pharmaceutical composition according to claim 22, wherein said composition is an aerosol formulation for administration to an animal's lungs.

### Claim 25 (depends on 22)

The pharmaceutical composition according to claim 22, wherein said bacteriophage is in lyophilized form.
